Design of High-Specificity Nanocarriers by Exploiting Non-Equilibrium Effects in Cancer Cell Targeting.
Although targeting of cancer cells using drug-delivering nanocarriers holds promise for improving therapeutic agent specificity, the strategy of maximizing ligand affinity for receptors overexpressed on cancer cells is suboptimal. To determine design principles that maximize nanocarrier specificity...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3694107?pdf=render |
id |
doaj-25e7da70d9bb4413baed8e3c9d3dad8d |
---|---|
record_format |
Article |
spelling |
doaj-25e7da70d9bb4413baed8e3c9d3dad8d2020-11-24T21:55:53ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0186e6562310.1371/journal.pone.0065623Design of High-Specificity Nanocarriers by Exploiting Non-Equilibrium Effects in Cancer Cell Targeting.Konstantinos TsekourasIgor GoncharenkoMichael E ColvinKerwyn Casey HuangAjay GopinathanAlthough targeting of cancer cells using drug-delivering nanocarriers holds promise for improving therapeutic agent specificity, the strategy of maximizing ligand affinity for receptors overexpressed on cancer cells is suboptimal. To determine design principles that maximize nanocarrier specificity for cancer cells, we studied a generalized kinetics-based theoretical model of nanocarriers with one or more ligands that specifically bind these overexpressed receptors. We show that kinetics inherent to the system play an important role in determining specificity and can in fact be exploited to attain orders of magnitude improvement in specificity. In contrast to the current trend of therapeutic design, we show that these specificity increases can generally be achieved by a combination of low rates of endocytosis and nanocarriers with multiple low-affinity ligands. These results are broadly robust across endocytosis mechanisms and drug-delivery protocols, suggesting the need for a paradigm shift in receptor-targeted drug-delivery design.http://europepmc.org/articles/PMC3694107?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Konstantinos Tsekouras Igor Goncharenko Michael E Colvin Kerwyn Casey Huang Ajay Gopinathan |
spellingShingle |
Konstantinos Tsekouras Igor Goncharenko Michael E Colvin Kerwyn Casey Huang Ajay Gopinathan Design of High-Specificity Nanocarriers by Exploiting Non-Equilibrium Effects in Cancer Cell Targeting. PLoS ONE |
author_facet |
Konstantinos Tsekouras Igor Goncharenko Michael E Colvin Kerwyn Casey Huang Ajay Gopinathan |
author_sort |
Konstantinos Tsekouras |
title |
Design of High-Specificity Nanocarriers by Exploiting Non-Equilibrium Effects in Cancer Cell Targeting. |
title_short |
Design of High-Specificity Nanocarriers by Exploiting Non-Equilibrium Effects in Cancer Cell Targeting. |
title_full |
Design of High-Specificity Nanocarriers by Exploiting Non-Equilibrium Effects in Cancer Cell Targeting. |
title_fullStr |
Design of High-Specificity Nanocarriers by Exploiting Non-Equilibrium Effects in Cancer Cell Targeting. |
title_full_unstemmed |
Design of High-Specificity Nanocarriers by Exploiting Non-Equilibrium Effects in Cancer Cell Targeting. |
title_sort |
design of high-specificity nanocarriers by exploiting non-equilibrium effects in cancer cell targeting. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2013-01-01 |
description |
Although targeting of cancer cells using drug-delivering nanocarriers holds promise for improving therapeutic agent specificity, the strategy of maximizing ligand affinity for receptors overexpressed on cancer cells is suboptimal. To determine design principles that maximize nanocarrier specificity for cancer cells, we studied a generalized kinetics-based theoretical model of nanocarriers with one or more ligands that specifically bind these overexpressed receptors. We show that kinetics inherent to the system play an important role in determining specificity and can in fact be exploited to attain orders of magnitude improvement in specificity. In contrast to the current trend of therapeutic design, we show that these specificity increases can generally be achieved by a combination of low rates of endocytosis and nanocarriers with multiple low-affinity ligands. These results are broadly robust across endocytosis mechanisms and drug-delivery protocols, suggesting the need for a paradigm shift in receptor-targeted drug-delivery design. |
url |
http://europepmc.org/articles/PMC3694107?pdf=render |
work_keys_str_mv |
AT konstantinostsekouras designofhighspecificitynanocarriersbyexploitingnonequilibriumeffectsincancercelltargeting AT igorgoncharenko designofhighspecificitynanocarriersbyexploitingnonequilibriumeffectsincancercelltargeting AT michaelecolvin designofhighspecificitynanocarriersbyexploitingnonequilibriumeffectsincancercelltargeting AT kerwyncaseyhuang designofhighspecificitynanocarriersbyexploitingnonequilibriumeffectsincancercelltargeting AT ajaygopinathan designofhighspecificitynanocarriersbyexploitingnonequilibriumeffectsincancercelltargeting |
_version_ |
1725860754372952064 |